

Contents

vi Preface

Puig, L. (Barcelona); Gulliver, W. (St. John's, NL)

vii Introduction – Biologics in Dermatology: Indications and Off-Label Usage

Puig, L. (Barcelona); Gulliver, W. (St. John's, NL)

1 Adverse Reactions to Biologics in Psoriasis

Lockwood, S.J.; Prens, L.M.; Kimball, A.B. (Boston, MA)

15 Clinical Trial and Registry Data

Gooderham, M. (Peterborough, ON/Waterloo, ON/Kingston, ON); Papp, K. (Waterloo, ON)

28 Immunosuppression/Infections across Indications

Al-Khalili, A.; Dutz, J.P. (Vancouver, BC)

37 The Immunogenicity of Biologic Therapies

Garcês, S. (Indianapolis, IN); Demengeot, J. (Oeiras)

49 Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others

Puig, L. (Barcelona)

64 Bullous Diseases

Corbaux, C.; Joly, P. (Rouen)

70 Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab

Saulite, I. (St. Gallen/Riga); Guenova, E. (St. Gallen/Zurich); Hoetzenecker, W. (St. Gallen/Linz)

82 Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab)

Hwang, S.J.E.; Fernández-Peñas, P. (Sydney)

93 Skin Manifestations of Targeted Antineoplastic Therapy

Sanmartín, O. (Valencia)

105 Author Index

106 Subject Index